Trials / Completed
CompletedNCT00898261
Gene Expression in Tissue From Patients With Acute Lymphoblastic Leukemia
Genetic Risk Classes in Adult Acute Lymphocytic Leukemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 137 (actual)
- Sponsor
- ECOG-ACRIN Cancer Research Group · Network
- Sex
- All
- Age
- 15 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at gene expression in tissue from patients with acute lymphoblastic leukemia enrolled in clinical trial ECOG-2993.
Detailed description
OBJECTIVES: * Identify genes involved in specific biologic processes or molecular functions that contribute to the mechanisms by which the BCR/ABL tyrosine kinase induces a leukemic phenotype using RNA banked from patients with BCR/ABL-positive acute lymphoblastic leukemia (ALL) enrolled on ECOG-2993. * Compare patterns of mRNA expression of BCR/ABL fusion protein in patients with B-lineage ALL vs patients with ALL and no cytogenetic abnormalities enrolled on ECOG-2993. * Determine both shared and differing expression patterns in patients with BCR/ABL-positive and cytogenetically negative ALL with respect to achievement of complete remission and duration of disease-free and overall survival. OUTLINE: This is a multicenter study. Total RNA is isolated from stored tissue samples and integrity is verified by reverse transcription-polymerase chain reaction (RT-PCR). cDNA libraries are created from total RNA and gene expression is analyzed via microarray analysis. Genes of interest are further analyzed by flow cytometry and RT-PCR. PROJECTED ACCRUAL: A total of 137 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | microarray analysis | |
| GENETIC | reverse transcriptase-polymerase chain reaction | |
| OTHER | flow cytometry |
Timeline
- Start date
- 2007-10-26
- Primary completion
- 2012-07-19
- Completion
- 2012-07-19
- First posted
- 2009-05-12
- Last updated
- 2017-05-19
Source: ClinicalTrials.gov record NCT00898261. Inclusion in this directory is not an endorsement.